BRAF and neoplasm: Inhibition of mutated BRAF using new specific BRAF inhibitors is reported in 2009 (ASCO) to be effective so that whether BRAF is a prognostic marker or not, BRAF driven MAPK pathway activation clearly drives tumor growth in melanoma tumors.